分化型甲状腺癌幸存者的癌症复发恐惧:一项系统综述
本系统综述检索6个电子数据库共3414项研究,最终纳入31项,评估分化型甲状腺癌幸存者癌症复发恐惧的发生率、影响因素及测量工具。27/31项研究报告发生率范围为15%至91%,但因定义界值异质性无法直接比较;年轻和即将临床随访为报告较多的危险因素,男性与较高教育水平为保护因素;未发现干预研究。
要点
- 27/31项研究报告癌症复发恐惧发生率范围为15%至91%,因界值异质性无法直接比较。
- 共使用8种经验证工具,5项研究使用自编未验证条目,工具重复少且无首选共识。
- 多项研究报告的危险因素包括年轻和即将临床随访,保护因素包括男性和较高教育水平。
核心结论
- 癌症复发恐惧在甲状腺癌幸存者中常见,但当前证据显著异质性限制了发生率、严重程度或危险因素的评估。
- 需要在研究和临床情境中使用经验证工具评估癌症复发恐惧。
- 可靠的癌症复发恐惧评估可能允许在临床实践中常规评估,并允许前瞻性评估干预措施以优化甲状腺癌幸存者的整体健康。
研究设计与样本
- 系统综述,检索6个电子数据库的英文文献,共生成3414项研究,由两名评价者独立筛选题录和全文,最终纳入31项研究,数据由两名评价者独立提取。
主要发现
- 27/31项研究报告了癌症复发恐惧的发生率,范围为15%至91%。
- 因用于定义癌症复发恐惧的界值存在异质性,无法对发生率和严重程度进行直接比较。
- 所有研究共使用8种经验证工具测量癌症复发恐惧,5项研究使用自编未验证条目。
- 11项研究报告了影响癌症复发恐惧的因素,各因素间重叠极少。
- 多于一项研究报告的增加癌症复发恐惧的危险因素包括年轻和即将临床随访;多于一项文章报告的男性性别和较高教育水平为保护因素。
关键数值与推荐
- 癌症复发恐惧发生率在27/31项研究中报告,范围为15%至91%。
- 共使用8种经验证工具测量癌症复发恐惧,5项研究使用自编未验证条目。
- 多于一项研究报告的危险因素:年轻、即将临床随访;保护因素:男性性别、较高教育水平。
临床怎么用
- 作者认为需要在研究和临床情境中使用经验证工具评估癌症复发恐惧。
- 作者认为可靠的癌症复发恐惧评估可能允许在临床实践中常规评估,并允许前瞻性评估干预措施以优化甲状腺癌幸存者的整体健康。
局限性
- 因用于定义癌症复发恐惧的界值存在异质性,无法对发生率和严重程度进行直接比较。
- 经验证工具重复使用极少,且对首选调查工具无明确共识。
- 影响癌症复发恐惧的因素在各研究间重叠极少。
- 未发现评估干预甲状腺癌幸存者癌症复发恐惧的文献。
- 当前证据基础的显著异质性限制了发生率、严重程度或危险因素的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Despite excellent survival rates, health-related quality of life detriments are common in differentiated thyroid cancer survivors and can be driven by fear of cancer recurrence (FCR). This review aims to report the incidence of FCR in thyroid cancer survivors and synthesize evidence regarding contributing factors. An overview and appraisal of the range of tools used to measure FCR is presented. Methods: A systematic review of the English literature was performed. The search across six electronic databases generated 3414 studies. Two reviewers independently screened the citations and full-text articles, of which 31 were included. The data were extracted independently by two reviewers. Results: The incidence of FCR was reported in 27/31 studies and ranged from 15% to 91%. Direct comparisons regarding incidence and severity of FCR were not possible due to heterogeneity in cut-points used to define FCR. A total of eight validated tools were used to measure FCR across all studies, with five studies using self-developed nonvalidated items. There was minimal repetition of validated tools and no clear consensus as to a preferred survey tool. Factors influencing FCR were reported in 11 studies. There was minimal overlap of factors influencing FCR. Risk factors contributing to increased FCR reported in more than one study included young age and an upcoming clinical appointment. Male gender and higher education levels were reported in more than one article as protective. No literature evaluating interventions to address FCR in thyroid cancer survivors was found. Conclusion: FCR is common in thyroid cancer survivors, but significant heterogeneity in the current evidence base limits assessment of incidence, severity, or risk factors. There is a need to use validated tools to assess FCR in both research and clinical contexts. Reliable assessment of FCR may permit routine assessment of FCR in clinical practice and allow interventions to be prospectively evaluated to optimize the holistic well-being of thyroid cancer survivors.
引用
- Hampton J, Alam A, Zdenkowski N, et al. Fear of Cancer Recurrence in Differentiated Thyroid Cancer Survivors: A Systematic Review. Thyroid. 2024. PMID: 38368547. doi:10.1089/thy.2023.0642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。